Hematological cancers present special opportunities for investors.  In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector. In the case of two companies with very different valuations, McCamant makes his preference clear.

The Life Sciences Report: I know you have great interest in cancer drug development. Do you see hematology/oncology (heme/onc) indications as areas of unmet need right now?

John McCamant: Heme/onc has been an area of success for biotech companies. We have seen …read more